Clinical Study

Ngm18-0402- A Phase 1A/B Dose-Escalation Study Followed By Expansion Cohorts Of Ngm120, A Gfral Antagonist Monoclonal Antibody Blocking Gdf15 Signaling, In Subjects With Advanced Solid Tumors And Pancreatic Cancer Using Combination Therapy

Posted Date: Feb 24, 2020

  • Investigator: Shuchi Gulati
  • Specialties: Cancer, Oncology, Pancreatic Cancer
  • Type of Study: Drug

The main goal of this study is to determine the safety and tolerability, and maximum tolerated dose of NGM120 alone, and NGM120 when administered in combination with gemcitabine+Abraxane in subjects with select solid tumors,for the management of metastatic pancreatic cancer.

Criteria:

To Be Eligible: Must Have Ecog 0-1, Life Expectancy >12 Weeks, Progressive Disease For Which No Effective Therapies Are Available, Active Infections Or Medical Disorders That May Impact Treatment

Keywords:

Pancreatic Cancer, Oncology

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.